Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety & PK of Pegolsihematide in MDS Anemia
NCT02619097Phase 1Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jun 2014
- Primary completion
- Dec 2015
- Modality
- PEGylated Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of peglmolesatide in anemia (5 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at 28 days, Maximum Plasma Concentration at 336 hours and 3 more. Status: unknown.
02
Drugs
peglmolesatide
03
Conditions
anemia
Beyond the preview
Go deeper on NCT02619097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02619097.